| Literature DB >> 27019747 |
Noah Jarari1, Narasinga Rao2, Jagannadha Rao Peela3, Khaled A Ellafi4, Srikumar Shakila3, Abdul R Said3, Nagaraja Kumari Nelapalli5, Yupa Min6, Kin Darli Tun7, Syed Ibrahim Jamallulail8, Avinash Kousik Rawal9, Ranjani Ramanujam10, Ramesh Naidu Yedla11, Dhilip Kumar Kandregula12, Anuradha Argi13, Laxmi Teja Peela14.
Abstract
Hypertension continues to be an important public health concern because of its associated morbidity, mortality and economic impact on the society. It is a significant risk factor for cardiovascular, cerebrovascular and renal complications. It has been estimated that by 2025, 1.56 billion individuals will have hypertension. The increasing prevalence of hypertension and the continually increasing expense of its treatment influence the prescribing patterns among physicians and compliance to the treatment by the patients. A number of national and international guidelines for the management of hypertension have been published. Since many years ago, diuretics were considered as the first-line drugs for treatment of hypertension therapy; however, the recent guidelines by the Joint National Commission (JNC8 guidelines) recommend both calcium channel blockers as well as angiotensin-converting enzyme inhibitors as first-line drugs, in addition to diuretics. Antihypertensive drug combinations are generally used for effective long-term management and to treat comorbid conditions. This review focuses on the antihypertensive medication utilization, their cost factors, adherence to treatment by patients, and physicians' adherence to guidelines in prescribing medications in different settings including Indian scenario. The antihypertensive medication prescribing pattern studies help in monitoring, evaluation and necessary modifications to the prescribing habits to achieve rational and cost-effective treatment. Additionally, periodic updating of recommended guidelines and innovative drug formulations, and prescription monitoring studies help in rational use of antihypertensive drugs, which can be tailored to suit the patients' requirements, including those in the developing countries.Entities:
Year: 2016 PMID: 27019747 PMCID: PMC4808570 DOI: 10.1186/s40885-016-0042-0
Source DB: PubMed Journal: Clin Hypertens ISSN: 2056-5909
Guideline comparisons of goal BP and initial drug therapy for adults with hypertension
| Guideline | Population | Goal BP, mmHg | Initial drug treatment options |
|---|---|---|---|
| JNC 8: 2014 Hypertension Guideline [ | General ≥60 y | <150/90 | Nonblack: thiazide-type diuretic, ACEI, ARB, or CCB; black: thiazide-type diuretic or CCB |
| General <60 y | <140/90 | ||
| Diabetes | <140/90 | ||
| CKD | <140/90 | ACEI or ARB | |
| ESH/ESC 2013 [ | General nonelderly | <140/90 | Diuretic, BB, CCB, ACEI, or ARB |
| General elderly <80 y | <150/90 | ||
| General ≥80 y | <150/90 | ||
| Diabetes | <140/85 | ACEI or ARB | |
| CKD no proteinuria | <140/90 | ||
| CKD + proteinuria | <130/90 | ||
| Canadian Hypertension Education Program (CHEP) 2014 [ | General <80 y | <140/90 | Thiazide, BB (age <60y), ACEI (nonblack), or ARB |
| General ≥80 y | <150/90 | ||
| Diabetes | <130/80 | ACEI or ARB with additional CVD risk ACEI, ARB, thiazide, or dihydropyridine CCB without additional CVD risk | |
| CKD | <140/90 | ACEI or ARB | |
| American Diabetes Association (ADA) 2013 [ | Diabetes | <140/80 | ACEI or ARB |
| Kidney Disease: Improving Global Outcome (KDIGO) 2012 [ | CKD, no proteinuria | ≤140/90 | ACEI or ARB |
| CKD + proteinuria | ≤130/80 | ||
| NICE 2011 [ | General <80 y | <140/90 | <55 y: ACEI or ARB |
| General ≥80 y | <150/90 | ≥55 y or black: CCB | |
| International Society for Hypertension in Blacks (ISHIB) 2010 [ | Black, lower risk | <135/85 | Diuretic or CCB |
| Target organ damage or CVD risk | <130/80 | ||
| Korean Society of Hypertension Guidelines for the Management of Hypertension 2013 [ | Elderly (>65 years) | <140/90 | ACEIs, CCBs and diuretics; BBs should be limited to special scenarios |
| Diabetes | <140/85 | ||
| Stroke, CAD and CKD | 140/90 | Combination therapy of ARBs, CCBs and diuretics |
Findings from different studies conducted to evaluate prescribing pattern of antihypertensive drugs
| Author name | No. subjects involved | Mono-/combination therapy prescribed | Antihypertensive drug class | Observation/Remarks |
|---|---|---|---|---|
| Caceres et al. [ | 100 % of the Extremadura population | Monotherapy | ARBs, ACEIs | Use of ARBs increased over ACEIs |
| Xu et al. [ | 59 hospitals’ databases | Monotherapy | CCBs, ARBs, ACEIs, BBs, and diuretics | The top-prescribed antihypertensive drug classes were CCBs and ARBs |
| Liu and Wang [ | 6,536 | Mono and combination | CCBs (17.7 %), CCBs + beta-blockers (7.7 %) | CCBs and BBs were the most prescribed antihypertensives |
| Joseph et al. [ | 165 | Two or more | CCB | 87.27 % prescriptions were found rational |
| Beg et al. [ | 645 | Two or more | ARB | 225 antihypertensives were from essential medicines list |
| Gu et al. [ | 9320 | Multiple | ARB | With Single pill combination 55 % likelihood of BP control |
| Al-Drabah et al. [ | 416 | Mono (192) | ACEIs | Most patients did not achieve target BP |
Observations from different studies highlighting antihypertensive drug utilization and adherence
| Author Name | Number of subjects involved | Observation/Remarks |
|---|---|---|
| Xavier et al. [ | 380 patients | Small doses of different classes of antihypertensive drug are more beneficial than a high dose of one |
| Shipra et al. [ | 22 prescription pattern monitoring studies | Antihypertensive utilization pattern is in accordance with the international guidelines different antihypertensive drug combinations in practice has a positive impact on the overall BP control |
| Murphy et al. [ | 51 studies | No significant differences in urban versus rural settings |
| Odili et al. [ | 501 case notes | Fair compliance with stated guidelines |
| Ahmad et al. [ | 13 doctors for 320 hypertensive patients | Doctors poorly adhered to Malaysian Clinical Practice Guideline (CPG)-2008 in hypertensive patients with diabetes and LVH. A better hypertension control was seen with ACEIs and guidelines-adherent therapy |
| Abdulameer et al. [ | 303 Cardiac complicated hypertension | 85.30 % adherence to guidelines |
Cost implication findings from various studies
| Author Name | Number of subjects involved | Mono-/combination therapy prescribed | Observation/Remarks |
|---|---|---|---|
| Rachana et al. [ | 300 prescriptions | Mono (48.94 %), CCB | Costliest - Alpha-blocker |
| Cost effective - Diuretic | |||
| Amira and Okubadejo [ | 225 black patients | CCB | Cost effective - Amiloride |
| Rimoy [ | 600 patients | Diuretics | Govt. shops drugs 5–6 times cheaper than private shops |
| Fisher and Avorn [ | 133,624 patients | Combination (CCB + ACEI) | Adherence to guidelines result in savings |
| Osibogun and Okwor [ | 147 prescriptions | Diuretics 79.6 % | Co-morbid conditions had high cost prescriptions |
Observations of antihypertensives use in special population from various studies
| Author Name | Number of Subjects Involved | Observation/Remarks |
|---|---|---|
| Altaf et al. [ | 100 geriatric patients | The drug class most commonly prescribed was CCBs and the anti-hypertensive drug combinations were considerable, and this practice impacted positively on the overall BP control. |
| Fadare et al. [ | 220 elderly patients | Antihypertensives accounted for 30.6 % prescriptions |
| Tondon et al. [ | 500 prescriptions to PMW | Adherence rates to JNC-7 were adequate in Stage 1, hypertensive emergency and urgency. It was inadequate in pre-hypertension and Stage 2 hypertension. |
| Dhanaraj et al. [ | 1186 hypertensive patients with type 2 DM patients | Adhered to guidelines |
| Janagan et al. [ | 85 hypertensive patients with type 2 DM | Prescription pattern was in accordance with the JNC 7 recommended treatment of hypertension with type 2 DM |
| Hussain et al. [ | 117 hypertensive patients with type 2 DM | Most common drug used was telmisartan. A positive relationship between fasting blood glucose and SBP observed. Underutilization of diuretics was noted. |
| Yoon et al. [ | 4296 adolescent hypertensives | Only 23 % received antihypertensive prescription |
| St. Peter et al. [ | 13072 adult patients on dialysis | Considerable proportions of patients with prescriptions for BBs, renin angiotensin system agents, and dihydropyridine CCBs in month 6 no longer had prescriptions for these medications by month 24. |